昊天國際建投(01341.HK)延長收購帝暉49%股權完成日期
格隆匯5月7日丨昊天國際建投(01341.HK)發佈公吿,於2021年4月26日,昊天國際建設投資、買方佳昌環球有限公司(昊天國際建設投資間接全資附屬公司及信銘生命科技間接非全資附屬公司)、賣方蘇俊豪先生及目標公司帝暉有限公司就收購事項訂立該協議,據此,買方已有條件同意收購目標公司現有已發行股本49%,總代價約為2.86億港元,將以昊天國際建設投資根據一般授權按發行價向賣方發行代價股份的方式償付。
買方、昊天國際建設投資、賣方與目標公司已於2021年5月7日訂立該協議的補充協議,將預期完成日期由2021年5月7日延長至2021年5月21日或可能經雙方書面協定的有關其他日期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.